Replies to post #128981 on Biotech Values

[oc631]

I refuse to see anything exciting about ABT's four drug DAA offering and we will never know all the reasons investors ran for the exit today. ABT was one/AF the other.

The majority of people have short attention spans and a lack of conviction which doesn't make for wise investing.



AF's YMB based journalism didn't help.